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Abstract
Background: Aging and migration have brought changes to the epidemiology and stroke has been shown to be
independently associated with Chagas disease. We studied stroke correlates in cardiomyopathy patients with focus on the
chagasic etiology.
Methodology/Principal Findings: We performed a cross-sectional review of medical records of 790 patients with a
cardiomyopathy. Patients with chagasic (329) and non-chagasic (461) cardiomyopathies were compared. There were 108
stroke cases, significantly more frequent in the Chagas group (17.3% versus 11.1%; p,0.01). Chagasic etiology (odds ratio
[OR], 1.79), pacemaker (OR, 2.49), atrial fibrillation (OR, 3.03) and coronary artery disease (OR, 1.92) were stroke predictors in
a multivariable analysis of the entire cohort. In a second step, the population was split into those with or without a Chagas-
related cardiomyopathy. Univariable post-stratification stroke predictors in the Chagas cohort were pacemaker (OR, 2.73),
and coronary artery disease (CAD) (OR, 2.58); while atrial fibrillation (OR, 2.98), age over 55 (OR, 2.92), hypertension (OR, 2.62)
and coronary artery disease (OR, 1.94) did so in the non-Chagas cohort. Chagasic stroke patients presented a very high
frequency of individuals without any vascular risk factors (40.4%; OR, 4.8). In a post-stratification logistic regression model,
stroke remained associated with pacemaker (OR, 2.72) and coronary artery disease (OR, 2.60) in 322 chagasic patients, and
with age over 55 (OR, 2.38), atrial fibrillation (OR 3.25) and hypertension (OR 2.12; p=0.052) in 444 non-chagasic patients.
Conclusions/Significance: Chagas cardiomyopathy presented both a higher frequency of stroke and an independent
association with it. There was a high frequency of strokes without any vascular risk factors in the Chagas as opposed to the
non-Chagas cohort. Pacemaker rhythm and CAD were independently associated with stroke in the Chagas group while age
over 55 years, hypertension and atrial fibrillation did so in the non-Chagas cardiomyopathies.
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Introduction
Chagas disease (CD) is caused by the flagellate protozoan
Trypanosoma cruzi and its main mechanism of transmission is
transcutaneous inoculation of the parasite by excreta of infected
insects [1–3]. Infection with T cruzi is an enzootic disease, which
can lead to human disease when the insect vectors—triatomine
bugs—reach their domestic cycle by infesting human mud houses
in poor communities. In non-endemic countries, blood transfu-
sion, organ transplantation, and vertical transmission are more
likely routes of infection [1,3–6]. Oral transmission, common in
the enzootic cycle [6], has only recently been reported in humans
[7,8]. An estimated 10 million people are infected worldwide,
mostly in Latin America and more than 25 million are at infection
risk [9–11]. Its annual death toll is estimated to claim 10,000 lives
[11,12] and the 10-year mortality rate may range from 9% to
85%, depending on clinical markers of cardiac damage [13].
Although vector transmission has been virtually interrupted in
most endemic countries [9], non-permanent sanitation control
[9,14,15], alternative transmission routes [7,8], escalating migra-
tion [4,12], and the increase in life expectancy have resulted in a
pressing pattern of Chagas cardiomyopathy on the overall burden
of chronic disease [4,16–18]. Nonetheless, Chagas disease is still
posted among the 20 most important neglected tropical diseases
[12].
There are two successive stages, an acute and a chronic phase.
The acute phase lasts 6 to 8 weeks, with spontaneous recovery in
more than 95% of patients. In the first years of the chronic phase,
most infected patients have no clinical evidence of an ongoing
illness. This stage of the chronic phase is called the indeterminate
form and in most patients it persists indefinitely [1–3,5,6]. Ten to
thirty years after it started, up to 30% of individuals will present
organ damage mainly affecting the heart muscle, leading to
Chagas cardiomyopathy which may result in severe cardiac
dilatation and contractile dysfunction [3–6], mostly due to a
parasite-triggered immune-mediated inflammation [19]. Patients
will often present malignant arrhythmias, heart blocks or
cardiogenic embolism; the latter one a common cause of ischemic
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35116stroke [3,5,6]. Likewise, stroke carries significant morbidity and
lethality [4,20,21], is often undertreated and is even considered the
most neglected aspect in the management of chagasic cardiomy-
opathy [5].
Although risk factors for ischemic stroke are reasonably
determined for many cardiac structural diseases, including the
dilated non-chagasic cardiomyopathies [21–23], they still have not
been properly established for patients with the chagasic cardio-
myopathy [5]. Few observational studies have been done on risk
correlates for stroke in Chagas cardiomyopathy, most have focused
on CD as a risk factor without establishing a differentiation
between CD itself and the chagasic cardiomyopathy and present
significant heterogeneity in sampling and methods [24–29]. Only
one study was performed specifically to determine the risk factors
for stroke in chagasic patients who already presented with a
cardiomyopathy [30]. The purpose of this study was to describe
the frequency of stroke correlates in a population presenting with a
cardiomyopathy, representative of a tertiary center in northeastern
Brazil with a specific focus on the chagasic etiology to define its
clinical profile according to stroke risk.
Methods
Ethics Statement
The Institutional Ethics Board of the Hospital Universitario
Professor Edgard Santos at the Federal University of Bahia
approved the study. The data were analyzed anonymously and the
Institutional Ethics Board waived consent.
The medical records of 806 non–selected consecutive patients
who demanded care between September/2003 and June/2008 in
a hospital-based outpatient cardiomyopathy clinic in the north-
eastern Brazilian state of Bahia were reviewed in this cross-
sectional single-center study. A diagnosis of cardiomyopathy was a
pre-requisite for admission and follow-up in this Clinic.
This specialized clinic utilizes a standardized protocol as a
medical record for routine patient care, which facilitates clinical
follow-up and allows for straightforward data retrieval whenever
required. This protocol covers full medical history and physical
examination, through the traditional systematic description of
symptoms and a structured yes/no (numeric) or quantitative
design. This section includes, among others, specific items on
dyspnea, edema, alcoholism, smoking status, hypertension,
diabetes mellitus, chronic renal failure, coronary artery bypass
graft (CABG) or percutaneous transluminal coronary angioplasty
(PTCA), coronary artery disease, stroke, permanent pacemaker
and cardioversion. Chagas serologic status, the regimen and
adherence to drug treatments, a complete physical examination,
detailed data on the electrocardiogram (ECG) and basal rhythm,
Holter monitoring, chest x-ray, echocardiogram, myocardial stress
scyntigraphy, cinecoronariography, blood chemistry and other
laboratory procedures are also included in this form. Hospital
admission and a non-scheduled visit to the clinic or emergency
room are specified by the precipitating event as stroke, resuscitated
cardiopulmonary arrest or cardioversion-requiring ventricular
tachycardia, pulmonary embolism, decompensated heart failure,
acute pulmonary edema, cardiac surgery, and any other verified
conditions, if there is a diagnosis. Conclusion sections include
information on the presence of clinical heart failure, functional
class and the most likely etiologic diagnosis with certification of
review by the medical staff.
A diagnosis of Chagas disease (CD) required a positive serologic
status that was defined by any combination of at least two positive
serologic tests for CD (indirect immunofluorescence, indirect
hemagglutination, or enzyme-linked immunosorbent assay) at data
collection (31;32), At Chart review, demographic, clinical data,
and available complementary diagnostic work-up were compliant
with the accepted published evidence [21,31–34].
A cardiomyopathy was defined as a structural disease of the
myocardium associated with cardiac dysfunction. They were
initially classified as dilated cardiomyopathy or a form of non-
dilated cardiomyopathy (hypertrophic, restrictive and arrhythmo-
genic right ventricular dysplasia) [34]. Dilated cardiomyopathy
was characterized by dilatation and impaired contraction of the
left ventricle or both ventricles; idiopathic, secondary to a specific
etiology or associated with a recognized cardiovascular disease in
which the degree of myocardial dysfunction was not explained by
the abnormal loading conditions or the extent of ischemic damage
[34].
Right bundle branch block, .1 ventricular premature beats
(VPB’s) by ECG either polymorphous or repetitive, non-sustained
ventricular tachycardia, 2
nd and 3
rd degree atrio-ventricular block,
sinus bradycardia ,40 beats/min, sinus node dysfunction, left
bundle branch block, atrial fibrillation, inactive segment and
primary alterations of ST-T wave are typical ECG changes in
Chagas cardiomyopathy by a Brazilian Expert Consensus [31].
Sinus bradycardia .40 beats/min, lone left anterior hemiblock,
non-specific ST-T changes, incomplete right bundle branch block,
1
st degree atrio-ventricular block and isolated VPB’s are non-
specific ECG changes by this Consensus.
Chagas cardiomyopathy was diagnosed only in patients
presenting a positive serologic status and one of the two following
characteristics: either typical ECG changes independently of the
presence of symptoms or nonspecific ECG changes plus typical
symptoms including a dilated heart with systolic dysfunction
[31,32]. Patients fulfilling the above criteria formed a Chagas
cardiomyopathy group and the remaining patients formed the
non-Chagas cardiomyopathy group.
Stroke was defined as a focal neurological impairment of sudden
onset, lasting more than 24 hours and of presumed vascular origin,
excluding symptoms associated with epidural and subdural
hemorrhage, poisoning, and those caused by trauma. A history
of global impairment or deep coma (subarachnoid hemorrhage or
coma of systemic vascular origin) was also an exclusion criterion,
since the outcome of interest was ischemic stroke. This was
adapted from the standard definition of the World Health
Organization that takes stroke as a clinically defined disease,
irrespective of access to technological equipments [33].
Clinical correlates were sorted based on prevalence, clinical
relevance, and availability. Age 55 was taken as an overall cut
point for vascular risk; current smokers were those who smoked for
over a year in their lifetimes and were still smoking; and current
alcohol overuse required drinking of more than five doses of a
distilled beverage per week at the time of evaluation. As
parameters for heart failure, the variables dyspnea and edema
were entered if there were shortness of breath at rest or upon
exertion and presence of dependent edema of the lower limbs,
respectively. Left ventricular dysfunction was categorized as an
ejection fraction below 45% in the echocardiogram. The variable
pacemaker referred to a permanent pacing device previously
implanted, cardioversion stood for a history of either resuscitated
cardiac arrest or cardioversion requiring ventricular tachycardia,
and any basal rhythm other than normal sinus was described as a
rhythm non-sinus, while other variables listed were self-explana-
tory.
Statistics
The unpaired t-test was used for continuous variables and
Pearson chi-square or Fisher’s exact test for categorical variables,
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adopted for the missing values at univariable analysis and a listwise
deletion for multivariable analysis. Baseline variables were
presented and compared between patients with or without Chagas
disease. Stroke correlates were compared between patients with or
without a stroke and variables with p,0.05, plus sex and
hypertension that is commonly associated with stroke in the
literature besides being highly frequent in our sample, were further
analyzed trough a logistic regression model with stroke as a
dependent variable. Next, we performed a post-stratification
analysis according to the etiology of the cardiomyopathy, as either
chagasic or non-chagasic. Only variables associated at the previous
step plus age, sex and hypertension were stratified. Further, we
took only variables with p,0,05 plus age and sex and applied a
dichotomous logistic regression model taking stroke as a
dependent variable. The statistical package for the social sciences
(SPSS 17.0 Inc., Chicago, Illinois) was employed.
Results
Eight hundred and six patients were seen in the Clinic through
this period. Information about a stroke diagnosis was missing for
16 individuals, leaving 790 available for analysis. Patients included
were 58.3+213.2 years old (437 [55.3%] males), 461 (58.4%)
presented a non Chagas-related cardiomyopathy and 329 (41.6%)
a Chagas-related cardiomyopathy. Within the non-Chagas group,
433 (54.8%) exhibited a dilated-type cardiomyopathy and 28
(3.5%) evidenced a form of non-dilated cardiomyopathy, either
restrictive or hypertrophic.
Since cases with missing information were excluded from
analysis through a variable-wise deletion, their number varied
down the column of clinical and demographic characteristics in
Table 1. The prevalences of clinical and demographic character-
istics (Table 1), both in the full cohort and in the split cohorts,
whether patients presented with or without a Chagas-related
cardiomyopathy, are also shown. There were 108 (13.7%) stroke
cases, 57 in the Chagas cohort and 51 in the non-Chagas cohort.
Vascular risk factors; smoking (p=0,005), hypertension (p,0.01),
diabetes (p=0.09), CABG or PTCA (p=0.001), coronary artery
disease (p,0.01) and chronic renal failure (p,0.04) exhibited
higher prevalences in the non-Chagas cohort. However, stroke was
more commonly seen in the Chagas cohort (17.3%) than in the
non-Chagas cohort (11.1%; p=0.01). Still, the prevalences of
pacemaker and rhythm non-sinus were significantly higher
(p=0.01) in the Chagas cohort.
Univariable correlates associated with stroke in the entire cohort
(Table 2) were age over 55 years, hypertension (marginally,
p=0,054), chagasic etiology, pacemaker, cardioversion, rhythm
non-sinus, atrial fibrillation and coronary artery disease. After
adjustment through multivariable analysis, chagasic etiology (OR
1.79), pacemaker (OR, 2.49), atrial fibrillation (OR, 3.03) and
coronary artery disease (OR, 1.92) persisted significantly associ-
ated with stroke. Left ventricular ejection fraction,45%, dyspnea
and edema were not associated with stroke.
In a second step, the population was split into two groups, those
without (Table 3) or with (Table 4) a Chagas related-cardiomy-
opathy. Univariable post-stratification stroke predictors in the
Chagas cohort (Table 4) were pacemaker (OR, 2.73; 95% CI,
1.38–5.39),and coronary artery disease (OR 2.58; 95% CI, 1.05–
6.36). In the non-Chagas cohort (Table 3), age over 55 (OR, 2.92;
95% CI, 1.42–5.98), atrial fibrillation (OR, 2.98; 95% CI, 1.26–
7.05), hypertension (OR, 2.62; 95% CI 1.28–5.39) and coronary
artery disease were (OR, 1.94; 95% CI, 1.03–3.66) were the post-
stratification univariable predictors. Vascular risk factors (VRFs),
smoking, hypertension, diabetes, CABG or PTCA, coronary
artery disease, and chronic renal failure were computed into a
single composite co-variable (VRFco). At an univariable analysis,
there was a high frequency of chagasic stroke patients without
VRFco (23 out of 56 / 40,4%) and this was clearly distinct from
non-chagasic stroke patients (6 out of 49/ 12,2%; p,0,001).
Taking patients without (Table 3) or with a Chagas related-
cardiomyopathy (Table 4) and further entering those data on a
dichotomous logistic regression model for multivariable adjust-
ment, stroke remained associated with age over 55 years (OR 2.38;
95% CI, 1.13–5.00), atrial fibrillation (OR 3.25; 95% CI, 1.32–
7.96) and marginally with hypertension (OR 2.12; p=0,052; 95%
CI, 0.99–4.51) in the 444 non-chagasic patients (Table 3).
Remaining predictors of stroke for the 322 chagasic patients
(Table 4) were pacemaker (OR=2.72; 95%CI: 1.37–5.40) and
coronary artery disease (OR=2.60; p=0.043; 95%CI:1.03–6.56).
Due to a variable number of cases available for each co-variable in
the logistic regression model, there were 17 missing cases in the
non-Chagas cohort and 7 in the Chagas cohort, remaining 104
patients with a stroke, 50 and 54 for each cohort respectively.
None of the pacemaker recipients presented concomitant atrial
fibrillation in the entire cohort. All patients with atrial fibrillation
were put on international normalized ratio (INR) adjusted long-
term warfarin treatment. Since warfarin treatment was more likely
a consequence than a cause of stroke in this population, or
otherwise it was prescribed to patients with classical risk factors
such as atrial fibrillation and heart failure combined, we did not
include it in the final analysis, as we are searching for additional
non-established risk factors for stroke in Chagas cardiomyopathy.
Discussion
Chagas disease and its related cardiomyopathy have long been
associated with thrombo-embolism and stroke in necropsy studies
[20,35,36]. Nonetheless, most clinical series have only been
reported in the last decade [24–30].
Apart from all previous reports, our study compares the cross-
sectional frequency of stroke and its correlates in patients with and
without a Chagas-related cardiomyopathy in a hospital-based
cardiomyopathy cohort. Our patients were predominantly over 55
years of age, male sex, non-white, with a high frequency of stroke
(108/790=13.7%) and Chagas cardiomyopathy (329/
790=41.6%). While stroke was more prevalent in the Chagas
cohort as compared to the non-Chagas cohort, there was a much
higher frequency of chagasic stroke patients without vascular risk
factors when compared to the non-Chagas cohort. Though we
came along with a singular design, our general findings are
consistent with at least two previous studies from Carod-Artal
which reported on Chagas disease and stroke in the emergency
department [24,25].
The core findings of our study, however, derive from an
additional two-step multivariable analysis. In the first step,
enclosing the entire cohort, Chagas etiology (OR=1.79), pace-
maker (OR=2.49), atrial fibrillation (OR=3.03), and coronary
artery disease (OR=1.92) were independently associated with
stroke. In the second step, a post-stratification dichotomous logistic
regression model was applied to the cohort, by splitting it into
Chagas and non-Chagas groups. In the Chagas group, pacemaker
(OR 2.72) and coronary artery disease (OR=2.60) remained as
independent predictors Though such association between stroke
and pacemaker rhythm has not been clearly reported, during
recent years, when most clinical series concerning Chagas disease
and stroke emerged [24–30], some of the data pointed in the same
direction. Carod-Artal showed an association for pacemaker
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of cases [25]. Whether a pacemaker rhythm itself may cause
dissinchrony and bring about stroke or stands as a surrogate
marker for other clinical variables, it was not possible to evaluate
in this study. While the association of pacemaker use in Chagas’
patients with stroke even after adjustment is interesting, this
finding needs both confirmation from prospective studies and
clarifying how pacemaker users differ from non-users. Still, since
the pathogenesis of CD itself makes it highly prone to embolism
[5,19], it may be hard to elicit supervening risk factors for
cardiogenic embolism.
On the other hand, some of the classical stroke risk factors, were
independent predictors in the non-Chagas group, namely age over
55 years (OR 2.38), atrial fibrillation (OR 3.25) and albeit
marginally, hypertension (OR 2.12; p=0,052). Noteworthy, the
strength of the association was particularly strong for atrial
fibrillation, post stratification, in the non-Chagas group. While
atrial fibrillation (AF) was not associated with stroke in the Chagas
cohort (unadjusted OR 1.94; 95% CI:0.85–4.43), it is necessary to
account for protection given by anticoagulation, since those
patients were treated with warfarin. Souza, in a recent cohort
study developed a stroke risk score for CD. However, AF could not
be within the score, since none of the patients with AF, all of them
on warfarin, presented a stroke during follow-up [29]. We admit
that AF, a well known risk factor for heart disease and stroke, also
entails risk for CD patients, yet due to its highly emboligenic
pathology [20], it may not impact to the same degree as in the
non-chagasic cardiomyopathies, besides the fact that the estab-
lished and well validated use of warfarin precludes a clinical trial.
Although our study could not show an association of stroke with
systolic dysfunction, this may be hard to demonstrate in a
transversal study, due to the very biological and sequential nature
of the myocardial pathology, whereas such association has already
been shown in at least two cohort studies [29,30]. Besides this,
since the two groups that we compared, Chagas and non-Chagas
related cardiomyopathies, are themselves associated with ventric-
ular dysfunction and embolism, what we have actually shown was
that they did not differ in this clinical aspect.
A small number of patients presented with coronary artery
disease (24/7.4%) in the Chagas cohort and its presence was
associated with stroke, adding further data on the changing
pattern of Chagas disease, in accordance with recently reported
trends [16;17]. Population ageing is leading to an increase in the
number of older adults infected with T. cruzi and age-related co-
morbidity is rising as most studies of the natural history of Chagas
disease have centered upon younger people [3,6].
Our study presents a number of limitations. Since our
population was derived from a Clinic where a Cardiomyopathy
represented a pre-requisite for admission, we have actually
described stroke correlates in cardiomyopathy patients with
emphasis on the Chagas-related cohort, taking the non-Chagas
cohort as a control group. Though we were apt to describe how
Table 1. Baseline Characteristics of 790 Cardiomyopathy Patients.
Clinical and demographic
characteristics Cases available Chagas disease p value
n% Yes No
(n=329 [41.6%]) (n=461 [58.4%])
Age (mean [SD]) 789 58.3 [13.2] 58.8 [11.4] 58.0 [14.3] 0.409
Age over 55 years 789 62.0 63.5 60.9 0.449
Male sex 790 55.3 53.5 56.6 0,384
Non-White 773 82.4 85.8 80.0 0,038
Alcohol abuse 779 7.3 5.8 8.4 0.176
Current smoker 790 15.6 11.2 18.7 0.005
Hypertension 789 54.4 42.1 63.1 0.000
Diabetes mellitus 789 11.8 9.5 13.4 0.086
Stroke 790 13.7 17.3 11.1 0.012
Pacemaker 789 8.2 15.2 3.3 ,0.001
Cardioversion
a 789 2.5 2.7 2.4 0.753
Rhythm non-sinus 789 27.0 35.6 20.9 0.000
Atrial fibrillation 789 8.2 10.0 7.0 0.122
LV dysfunction
b 621 66.8 71.1 63.7 0.530
Dyspnea 789 86.3 86.0 86.6 0.817
Edema 778 60.8 62.7 59.5 0.370
Left heart thrombus 599 2.8 2.9 2.8 0.936
CABG or PTCA
c 776 4.1 1.2 6.2 0.001
Coronary artery disease 772 16.1 7.4 22.4 ,0.001
Chronic renal failure 785 6.5 4.3 8.0 0.036
SD: standard deviation.
aCardioversion for ventricular tachycardia or cardiac arrest.
bLeft ventricular ejection fraction below 45%.
cCoronary artery bypass graft or percutaneous transluminal coronary angioplasty.
doi:10.1371/journal.pone.0035116.t001
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stroke risk factors, we could not broadly point at stroke predictors
due to lack of a non-cardiopathy control group. Whereas all
information originated from a Clinic attending patients with a
previously structured protocol as a medical record, data retrieval
for this specific study was retrospective, followed by a cross-
sectional analysis, and so it lacked statistical power for definite
recommendations. Yet, since no data were collected regarding the
pacemaker carriers, we could not ascertain whether the type of
pacemaker played a role or how carriers differed from non-carriers
Table 2. Clinical and Demographic Correlates of Stroke in 790 Cardiomyopathy Patients.
Clinical and demographic
correlates Cases available (n) Stroke (%): Unadjusted p value
a Adjusted odds ratio
b
95% confidence
interval
YES NO
Age over 55 789 72.2 60.4 0.018 1.41 0.87–2.27
Male sex 790 52.8 55.7 0.568 0.98 0.64–1.50
Non-white 773 87.6 81.6 0.131 … …
Alcohol abuse 779 6.5 7.5 0.719 … …
Current smoker 790 12.0 16.1 0,276 … …
Hypertension 789 63.0 53.0 0,054 0.69 0.43–1.10
Diabetes mellitus 789 13.9 11.5 0.466 … …
Chagasic etiology 790 52.8 39.9 0,012 1.79 1.13–2.84
Pacemaker 789 15.7 7.0 0,002 2.49 1.08–5.77
Cardioversion
c 789 6.5 1.9 0,005 2.26 0.80–6.43
Rhythm non-sinus 789 36.1 25.6 0,022 0.78 0.38–1.60
Atrial fibrillation 789 15.7 7.0 0,002 3.03 1.33–6.94
LV dysfunction
d 621 69.8 66.4 0.533 … …
Dyspnea 789 84.3 86.6 0.504 … …
Edema 778 69.2 59.5 0,056 … …
Left heart thrombus 599 1.3 3.1 0.392 … …
CABG or PTCA
e 776 0.9 4.6 0.110 … …
Coronary artery disease 772 23.4 14.9 0,027 1.92 1.12–3.31
Chronic renal failure 785 9.3 6.1 0.210 … …
aUnadjusted results based on Pearson chi-square or Fisher’s exact test as appropriate.
bAdjusted results based on logistic regression, including all variables with unadjusted p,0.05. Missing cases were 22 due to listwise deletion. 768 patients remained in
the analysis, 107 with a stroke and 661 without a stroke.
cCardioversion for ventricular tachycardia or cardiac arrest.
dLeft ventricular ejection fraction below 45%.
eCoronary artery bypass graft or percutaneous transluminal coronary angioplasty.
doi:10.1371/journal.pone.0035116.t002
Table 3. Stroke Correlates in Non-Chagasic Patients.
Clinical correlates Stroke (n)
Unadjusted odds
ratio
a
95% confidence
interval
Adjusted odds
ratio
b
95% confidence
interval
Yes (51) No (410)
n% n %
Age over 55 years 41 80.4 239 58.4 2.92 1.42–5.98 2.38 1.13–5.00
Male Sex 29 56.9 232 56.6 0.99 0.55–1.78 1.00 0.54–1.85
Pacemaker 1 2.0 14 3.4 0.56 0.07–4.38 … …
Atrial fibrilation 8 15.7 24 5.9 2.98 1.26–7.05 3.25 1.32–7.96
Hypertension 41 80.4 250 61.0 2.62 1.28–5.39 2.12 0.99–4.51
CAD 17 34.0 83 21.0 1.94 1.03–3.66 1.50 0.77–2.92
aUnadjusted results based on Pearson chi-square or Fisher’s exact test as appropriate. See text for explanation on how variables were previously selected. All 461 non-
chagasic patients were included in the analysis.
bAdjusted results based on logistic regression, all listed variables included. See text for explanation on how variables were previously selected. Missing cases were 17
due to listwise deletion. 444 patients remained in the analysis, 50 with a stroke and 394 without a stroke.
CAD: Coronary artery disease.
doi:10.1371/journal.pone.0035116.t003
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sample cohort-type study in this population with focus on stroke
predictors and complete clinical information on pacemaker
carriers which should allow for an improved understanding about
Chagas disease and stroke in that particular area.
We have identified three areas of particular interest in our
study. First, not only chagasic patients presented a high prevalence
of stroke (17.3%, 1 in 6 patients) but the Chagas-related
cardiomyopathy was independently associated with it. Second,
there was a high frequency of stroke patients in the chagasic cohort
without vascular risk factors (40%, p,0.001), while just about 1 in
10 patients in the non-chagasic cohort (12%) presented a stroke
without any vascular risk factors, suggesting other potential
mechanisms intrinsic to Chagas cardiomyopathy.
Third, in a direct multivariable cross-sectional comparison
between patients with a Chagas-related cardiomyopathy and those
with non-Chagas cardiomyopathies, stroke was associated with age
over 55 years, atrial fibrillation and hypertension in the non-
Chagas group and just pacemaker and coronary artery disease in
the Chagas group, in which a highly emboligenic pathogenesis
may limit the determination of supervening stroke risk factors. We
reinforce the idea that further studies are warranted in those
particular areas.
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